BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7190
- TODAY'S CHANGE (%)0.0340 (4.9635%)
- Bid / Lots0.7000/ 10
- Ask / Lots0.7100/ 16
- Open / Previous Close0.6948 / 0.6850
- Day Range
- 52 Week Range
- Volume1,340,551
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 51151 | 0.72995 |
| 09:34 ET | 10567 | 0.727 |
| 09:36 ET | 7075 | 0.71 |
| 09:38 ET | 15261 | 0.7101 |
| 09:39 ET | 9007 | 0.72 |
| 09:41 ET | 6422 | 0.7101 |
| 09:43 ET | 8026 | 0.7101 |
| 09:45 ET | 118900 | 0.7 |
| 09:48 ET | 28241 | 0.685 |
| 09:50 ET | 500 | 0.6909 |
| 09:52 ET | 130 | 0.6879 |
| 09:54 ET | 37204 | 0.6879 |
| 09:56 ET | 39918 | 0.7 |
| 09:57 ET | 3870 | 0.688 |
| 09:59 ET | 3932 | 0.688 |
| 10:01 ET | 28069 | 0.686 |
| 10:06 ET | 1000 | 0.686 |
| 10:08 ET | 20700 | 0.6925 |
| 10:10 ET | 5622 | 0.685 |
| 10:19 ET | 5222 | 0.685 |
| 10:21 ET | 2650 | 0.6808 |
| 10:24 ET | 400 | 0.689 |
| 10:26 ET | 6428 | 0.6922 |
| 10:28 ET | 5187 | 0.7 |
| 10:30 ET | 7430 | 0.6905 |
| 10:32 ET | 400 | 0.6945 |
| 10:33 ET | 600 | 0.7 |
| 10:35 ET | 17699 | 0.6834 |
| 10:37 ET | 2094 | 0.7 |
| 10:39 ET | 800 | 0.685 |
| 10:42 ET | 343 | 0.6963 |
| 10:48 ET | 100 | 0.6902 |
| 10:51 ET | 45945 | 0.671 |
| 10:53 ET | 1500 | 0.6806 |
| 10:55 ET | 3150 | 0.671 |
| 10:57 ET | 16588 | 0.66 |
| 11:00 ET | 4461 | 0.65 |
| 11:02 ET | 2408 | 0.6562 |
| 11:04 ET | 1400 | 0.652 |
| 11:08 ET | 9815 | 0.6649 |
| 11:09 ET | 7693 | 0.67 |
| 11:11 ET | 6083 | 0.6599 |
| 11:13 ET | 500 | 0.665 |
| 11:15 ET | 183 | 0.676899 |
| 11:18 ET | 10322 | 0.66 |
| 11:20 ET | 600 | 0.68 |
| 11:22 ET | 9000 | 0.66 |
| 11:24 ET | 151 | 0.6724 |
| 11:29 ET | 3200 | 0.67 |
| 11:31 ET | 2692 | 0.67 |
| 11:33 ET | 200 | 0.6701 |
| 11:36 ET | 150 | 0.6847 |
| 11:44 ET | 4264 | 0.6893 |
| 11:45 ET | 534 | 0.6901 |
| 11:49 ET | 4390 | 0.69505 |
| 11:51 ET | 100 | 0.6901 |
| 11:56 ET | 1088 | 0.67 |
| 11:58 ET | 100 | 0.685 |
| 12:00 ET | 10998 | 0.67 |
| 12:02 ET | 500 | 0.67 |
| 12:05 ET | 1000 | 0.6849 |
| 12:09 ET | 2322 | 0.685 |
| 12:12 ET | 100 | 0.695 |
| 12:23 ET | 100 | 0.6851 |
| 12:30 ET | 11190 | 0.6987 |
| 12:32 ET | 894 | 0.6987 |
| 12:38 ET | 1720 | 0.685001 |
| 12:41 ET | 23091 | 0.69 |
| 12:43 ET | 7225 | 0.6847 |
| 12:50 ET | 1100 | 0.6801 |
| 01:08 ET | 17465 | 0.685 |
| 01:12 ET | 1000 | 0.68745 |
| 01:14 ET | 15746 | 0.66 |
| 01:19 ET | 720 | 0.6612 |
| 01:24 ET | 10046 | 0.6676 |
| 01:26 ET | 100 | 0.6788 |
| 01:30 ET | 6085 | 0.6676 |
| 01:35 ET | 2920 | 0.684899 |
| 01:53 ET | 477 | 0.6675 |
| 01:55 ET | 1900 | 0.676778 |
| 01:57 ET | 1400 | 0.6675 |
| 02:00 ET | 500 | 0.6791 |
| 02:11 ET | 13597 | 0.68 |
| 02:13 ET | 100 | 0.68 |
| 02:15 ET | 958 | 0.67 |
| 02:27 ET | 1000 | 0.675051 |
| 02:29 ET | 3600 | 0.6701 |
| 02:36 ET | 1600 | 0.678157 |
| 02:42 ET | 681 | 0.6799 |
| 02:44 ET | 3200 | 0.685 |
| 02:45 ET | 10521 | 0.67 |
| 02:47 ET | 216 | 0.685 |
| 02:51 ET | 2000 | 0.6821 |
| 02:54 ET | 258 | 0.6849 |
| 03:05 ET | 9200 | 0.67 |
| 03:12 ET | 5825 | 0.678 |
| 03:20 ET | 100 | 0.677999 |
| 03:21 ET | 2100 | 0.671 |
| 03:23 ET | 1300 | 0.6849 |
| 03:25 ET | 17255 | 0.69 |
| 03:27 ET | 25034 | 0.73 |
| 03:30 ET | 5128 | 0.7 |
| 03:32 ET | 545 | 0.6704 |
| 03:34 ET | 750 | 0.671 |
| 03:36 ET | 1100 | 0.6856 |
| 03:38 ET | 3100 | 0.6899 |
| 03:39 ET | 1974 | 0.6899 |
| 03:41 ET | 23494 | 0.682606 |
| 03:45 ET | 300 | 0.6814 |
| 03:48 ET | 100 | 0.69 |
| 03:54 ET | 16553 | 0.7175 |
| 03:56 ET | 10000 | 0.6953 |
| 03:57 ET | 1160 | 0.7099 |
| 03:59 ET | 7594 | 0.71 |
Today
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 13 hours ago by Dow Jones
13 hours ago by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 13 hours ago by Dow Jones
13 hours ago by Dow Jones
May 24, 2024
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, from 7:00AM ET on Friday May 24, 2024 by Dow Jones
7:00AM ET on Friday May 24, 2024 by Dow Jones
May 22, 2024
BioLineRx to Report First Quarter 2024 Results on May 28, 2024, from 7:00AM ET on Wednesday May 22, 2024 by Dow Jones
7:00AM ET on Wednesday May 22, 2024 by Dow Jones
May 17, 2024
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification, from 5:00PM ET on Friday May 17, 2024 by Dow Jones
5:00PM ET on Friday May 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 56.4M | -0.8x | --- |
Dyadic International Inc | 57.0M | -7.2x | --- |
Kezar Life Sciences Inc | 51.3M | -0.5x | --- |
Evogene Ltd | 41.5M | -1.7x | --- |
Kronos Bio Inc | 45.4M | -0.4x | --- |
Palatin Technologies Inc | 32.3M | -0.8x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $56.4M |
|---|---|
Revenue (TTM) | $4.8M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.95 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 11.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,035.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
